Print this page    •   Back to Web version of article

Medical News
Merck Says Hepatitis Pill Hampers HIV Drugs

February 13, 2012

Merck & Co.'s hepatitis C virus (HCV) treatment Victrelis (boceprevir) considerably lessens the effectiveness of some widely used HIV drugs, U.S. regulators and Merck recently announced.

"These drug interactions may be clinically significant for patients infected with both chronic hepatitis C virus and HIV by potentially reducing the effectiveness of these medicines when co-administered," Merck said in a Feb. 6 letter to health care professionals.

The drug interactions were seen in a study of healthy volunteers who took Victrelis, which is an HCV protease inhibitor, and certain HIV protease inhibitors boosted by Norvir (ritonavir). Victrelis reduced the concentrations in the blood of Reyataz (atazanavir), Prezista (darunavir), and Kaletra (lopinavir/ritonavir) an average of 49 percent, 59 percent, and 43 percent, respectively. Levels of Victrelis itself were reduced by 45 percent among those taking it with Kaletra, and 32 percent among those taking it in combination with Norvir and Prezista.

Patients should not stop taking any of their medicines without talking to health care professionals. Drug interactions have previously been found between Victrelis and the non-nucleoside reverse transcriptase inhibitor Sustiva (efavirenz). Merck said it is conducting drug-interaction studies for other HIV drugs, including the NNRTI Intelence (etravirine) and the integrase inhibitor Isentress (raltegravir).

For more information, visit: www.fda.gov/Drugs/DrugSafety/ucm291119.htm.


Back to other news for February 2012

Excerpted from:
Reuters
02.09.2012; Randsell Pierson




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/65735/merck-says-hepatitis-pill-hampers-hiv-drugs.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.